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Peritoneal defense in continuous ambu'atory peritoneal dialysis versus
continuous cyclic peritoneal dialysis. Several centers have reported a
lower rate of peritonitis among adult patients on Continuous cyclic
peritoneal dialysis (CCPD) as compared to those undergoing continuous
ambulatory peritoneal dialysis (CAPD). Preliminary results of our
ongoing prospective randomized study comparing CAPD-Y with CCPD
also suggest a lower peritonitis incidence among CCPD-treated pa-
tients. To investigate whether the two dialysis regimens could result in
differences in local host defense, we studied peritoneal macrophage
(PMO) function and effluent opsonic activity in eight patients estab-
lished on CAPD-Y matched with eight chronic CCPD patients. Since
short and long dwell times are inherent to both dialysis modalities, and
we previously found that dwell time has an impact on PMO function and
effluent opsonic activity, patients were studied after both a short (4 hr)
and a long (15 hr) dwell time. In both patient groups PMO phagocytic
capacity increased significantly with dwell time (39 3.3% at 4 hr vs.
58 4.2% at 15 hr in CAPD patients, and 40 3.9 vs. 72 3.3% in
CCPD patients; P < 0.01), as did PMO peak chemiluminescence
response (31 4.9 vs. 77 7.2 counts min'/l04 cells in CAPD, and
22 3.9 vs. 109 21.2 counts min/l04 cells in CCPD; P < 0.01)
and effluent opsonic activity (41 7.6 vs. 73 5.8% in CAPD and 39
6.2 vs. 70 5.9% in CCPD; P < 0.01). However, no significant
difference was found in either variable between CAPD and CCPD
patients when dwell times were equal. In conclusion, no differences
were observed in PMO function or effluent opsonic activity between
matched CAPD-Y and CCPD patients when dwell times were equal. In
both patient groups prolongation of dwell time enhanced PMO function
as well as effluent opsonic activity, thereby providing a better host
defense. The improvement in peritoneal defenses may, in part, be
responsible for the lower peritonitis incidence observed among CCPD-
treated patients.
Peritoneal dialysis has become an increasingly applied treat-
ment modality for patients with end-stage renal disease. How-
ever, bacterial peritonitis still is the major complication of
continuous ambulatory peritoneal dialysis (CAPD), resulting in
relatively high morbidity and drop-out rates [1]. Several centers
applying continuous cyclic peritoneal dialysis (CCPD) on a
large scale have reported significantly lower rates of peritonitis
among adult CCPD patients as compared to those undergoing
CAPD [2, 3]. Preliminary results of our ongoing prospective
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randomized study comparing CAPD and Y-connector
(CAPD-Y) with CCPD also suggest a lower peritonitis incidence
among CCPD-treated patients [4]. The lower peritonitis inci-
dence observed in CCPD as compared to CAPD has primarily
been associated with the fewer (dis)connections needed in
CCPD. However, local defense mechanisms may also play an
important role in the prevention of and recovery from bacterial
peritonitis; in this respect ingestion and killing of microorgan-
isms by peritoneal macrophages are thought to be essential [5].
Because the dialysis regimens inherent to CAPD and CCPD,
respectively, differ primarily in their dwell time periods preced-
ing exchange procedures, we studied PMO function and effluent
opsonic activity after both a short (4 hr) and a long (15 hr) dwell
time in eight CAPD-Y patients matched with eight CCPD
patients.
Methods
Patients and study design
Eight stable CAPD-Y patients [4 men and 4 women, median
age 55 years (35 to 76) and on CAPD for a mean SD period of
26.6 14 months] matched with eight CCPD patients [5 men, 3
women, median age 53.5 years (37 to 73) and on CCPD for a
mean SD of 25.8 12.9 months] were studied. The etiologies
of end-stage renal failure were glomerulonephritis (2 patients),
interstitial nephritis (2 patients), nephrosclerosis (2 patients),
diabetic nephropathy (2 patients) for the CAPD-Y group, and
glomerulonephritis (2 patients), interstitial nephritis (3 pa-
tients), nephrosclerosis (2 patients) and diabetic nephropathy (1
patient) for those on CCPD. At time of study entry, there was
no evidence of peritonitis (that is, no symptoms and clear
effluents with less than 100 WBC/mm3 for at least 4 weeks prior
to participation). In a randomized cross-over setting each
patient performed the first exchange (2 liters of Dianeal®,
containing 2.27% glucose, Baxter Ltd., Thetford, UK) of study
day one after a dwell time of 4 or 15 hours. The next day, the
patients who had performed the first exchange of study day one
after a dwell time of 4 hours, exchanged their first bag (2 liters
of Dianeal®, containing 2.27% glucose) after a dwell time of 15
hours and vice versa. The peritoneal effluents were collected
and studied for total WBC and differential count, IgG and C3
concentration, as well as opsonic activity for Staphylococcus
aureus. Functional studies of PMO isolated from the effluents
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included both their phagocytic capacity and their ability to
mount a respiratory burst upon stimulation. The study had been
approved by the Ethical Review Committee of the Free Uni-
versity Hospital and informed consent was obtained from all
patients.
Phagocytic cells
Peritoneal macrophages (PMO) were isolated from the efflu-
ents as previously described [61. Final resuspensions were
made in Hank's balanced salt solution containing 0.1% gelatin
(GHBSS) to a concentration of 5 x 106 PMO/ml. Total and
differential cell counts were performed on all samples. Viability
was assessed by the trypan blue exclusion test. Test-control
phagocytes were peripheral blood polymorphonuclear leuco-
cytes (PMN) isolated from 50 ml sterile, heparinized venous
blood of healthy donors using dextran sedimentation and a
Ficoll gradient [7], and were also used at a concentration of 5 X
106 cells/ml.
Bacteria
A clinical isolate of S. aureus, obtained from a CAPD patient
with peritonitis was used. Bacteria were radiolabeled by grow-
ing them in 10 ml of Mueller-Hinton broth (Difco Laboratories,
USA) containing 20 tCi 3H-adenine (ICN, USA) in a shaking
incubator for 18 hours at 37°C [10]. Subsequently, bacteria were
washed three times with phosphate-buffered saline (PBS) and
resuspended in GHBSS to a concentration of 5 X 108 cfu/ml [8].
Opsonins and opsonization procedure
A pool of human serum (HPS) obtained from ten healthy
(HBs-antigen and HIV antibodies negative) donors, stored at
—70°C, was used as source of opsonins. Immediately prior to
use, serum was thawed and diluted to a final concentration of
5% in GHBSS. Suspensions of bacteria (0.1 ml containing
approximately 5 x io microorganisms) were mixed with 0.9 ml
of 5% HPS and incubated in a shaking water bath for 30 minutes
at 37°C. Opsonization was stopped by adding 2.5 ml ice-cold
PBS. Subsequently, the suspensions were centrifuged at 3000
rpm for 15 minutes, the supernatants discarded, and the bacte-
rial pellets resuspended in 1 ml GHBSS and kept at 4°C until use
(preopsonized bacteria).
Cell-free effluents were also stored at —70°C until they were
likewise used as source of opsonins to test their opsonic
activity. The effluents, however, were used undiluted. In addi-
tion part of the serum and effluents were heated (56°C for 30
mm) to deplete them of heat-labile opsonins prior to their use.
Phagocytosis assay
The uptake of preopsonized S. aureus by PMO was deter-
mined using an assay that has been described in detail [7]. In
brief, 100 d of bacteria preopsonized with 5% HPS was mixed
with 100 pi of PMO in a final bacteria to phagocyte ratio of 10:1.
In parallel, donor PMN incubated with the same preopsonized
cocci were run as control. Phagocytosis was allowed to proceed
for 60 minutes in a shaking incubator at 37°C. Phagocytosis was
stopped by adding 2.5 ml of ice cold PBS. Non-phagocyte-
associated bacteria were removed by centrifugation (1200 rpm
for 5 mm), washing three times with ice cold PBS followed by
three cycles of centrifugation (1200 rpm for 5 mm). The phago-
cyte-associated radioactivity was determined by liquid scintil-
lation counting [9]. Phagocytosis was expressed as percentage
uptake of total radioactivity added, which was determined in a
separate vial [7].
Assessment of effluent opsonic activity for S. aureus
The uptake of radiolabeled S. aureus, preopsonized in undi-
luted effluent, by PMN, was taken as a measure of effluent
opsonic activity (see phagocytosis assay). Bacteria, preop-
sonized with 5% HPS, were used as controls in each experi-
ment. The concentrations of IgG and C3 in effluent were
measured nephelometrically using a Beckmann protein assay
(Beckmann, Mijdrecht, The Netherlands).
Chemiluminescence assay
The microchemiluminescence assay described by Mills,
Rholl and Quie [10] was modified and used to measure the
oxidative metabolic responses of PMO obtained after different
dwell times. Amplification of the chemiluminescence signal was
obtained by adding luminol (0.03 mmol/ml in GHBSS; Sigma
Chemical, St. Louis, Missouri, USA). Chemiluminescence mix-
tures, in transparent plastic scintillation vials, contained 800 sl
GHBSS, 100 d PMO or PMN (1 x l0 cells/mi), and 70 pi
luminol. Phagocyte chemiluminescence was activated by add-
ing 100 d phorbol myristate acetate (PMA; 50 ng/ml in GHBSS;
Sigma Chemicals). Backgrounds were measured in separate
vials devoid of stimuli (100 d GHBSS instead of PMA). After
stimulation, counts were obtained every two minutes for 30
minutes at 37°C. Results were recorded as the peak number of
counts per minute per lO cells after subtracting background
counts.
Data analysis
Paired two-tailed Wilcoxon signed rank tests were used for
the comparison of the matched CAPD-Y versus CCPD patients
at a given dwell time and for the comparison of short versus
long dwell time within either dialysis modality, where the
patients served as their own controls. A probability of 5% was
chosen as level of significance.
Results
The effluent total white cell count from both CAPD and
CCPD patients increased significantly with dwell time; at 4
hours and 15 hours the WBC was 2.6 0.46 versus 6.7 0.64
x 10 cells/liter, respectively, in CAPD patients, and 2.2 0.38
versus 6.2 0.66 x 10 cells/liter, respectively, in CCPD
patients (P < 0.01). However, there was no change in cellular
composition of the effluents; the overall white cell differentia-
tion was 89% PMO (range 82 to 93%), 7% lymphocytes (4 to
9%), 3% PMN (2 to 5%) and 1% mesothelial cells (0 to 2%).
Viability was always over 90%. PMO obtained after a 15-hour
dwell time period revealed a significantly better uptake of S.
aureus as compared to PMO obtained after a dwell of 4 hours,
whereas no significant difference was found between PMC
phagocytic capacity of CAPD and CCPD patients when dwell
times were equal (Table 1).
The same held true for PMO chemiluminescence response,
reflecting the ability of PMO to mount a respiratory burst, that
is, to produce toxic oxygen radicals upon stimulation with
PMA: PMO derived from both CAPD and CCPD patients after
a dwell time of 15 hours revealed a significantly higher peak
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Data are mean SEM. Abbreviation is: CL, chemiluminescence in
counts per mm per io cells.
a p < 0.01 vs. 4 hr; Control phagocytes (PMN; N = 8) phagocytized
86 1.97% of S. aureus, and their chemiluminescence response was
954 64.3 counts min'/104 cells
Table 2. Effluent opsonic activity and IgG- and C3 levels after
different dwell times
Dwell
time (hr) CAPD CCPD
Total opsonic activity 4 41 7.6 39 6.2
(OA) % IS 73 5.8k 70 5.9


















Data are mean SEM.
a P <0.01 vs. 4 hr; b P>0.l vs. 4 hr; Control OA (5% HPS) was 83%
and 31%, respectively, for unheated and heated serum.
chemiluminescence as compared to PMO harvested from the
same patients after a dwell time of 4 hours, whereas no
significant difference was observed in chemiluminescence re-
sponse of PMO obtained from CAPD versus CCPD patients
after the same dwell time (Table 1). Since IgG is a major
heat-stable opsonin and C3 is an important component of the
heat-labile opsonic system, IgG and C3 concentrations were
determined in all peritoneal dialysis effluents. As shown in
Table 2, the mean effluent IgG level increased significantly with
dwell time, and did not differ between CAPD and CCPD
patients at a given dwell time. C3 was below the lower limit of
detection (0.01 glliter) in all 4 hour effluents, and could be
detected in all 15 hour effluents (Table 2).
In both patient groups effluent opsonic activity was signifi-
cantly higher in the 15 hour effluents than in the 4 hour effluents
(Table 2). Heat-stable effluent opsonic activity also increased
with dwell time, however, not significantly so, suggesting that
the major increase in effluent opsonic activity with dwell time
was due to heat-labile component(s). That the opsonic require-
ment of the S. aureus strain used in this study is largely
dependent on heat-labile factor(s) was also reflected in the
results obtained when heated versus unheated 5% HPS was
used as opsonic source (31% vs. 83% uptake, Table 2).
Discussion
This comparative study in patients on long-term continuous
peritoneal dialysis revealed no significant differences in effluent
white cell count, differentiation, viability, peritoneal macro-
phage function and effluent opsonic activity between CAPD
patients and those undergoing CCPD when dwell times were
equal. However, in both patient groups prolongation of the
dwell time was associated with improvements in peritoneal
macrophage functions as well as in the opsonic activity of the
effluent fluids. Thus longer dwell times are accompanied by an
improvement in the phagocytic defense of the peritoneal cavity.
Bacterial peritonitis still is the major complication in patients
with end-stage renal failure maintained on chronic peritoneal
dialysis [I]. Since the peritoneal macrophage, as the predomi-
nant cell in dialysate, constitutes the first line of cellular defense
against bacterial invasion into the peritoneal cavity [5], inves-
tigations targeting at the effect of peritoneal dialysis on their
functions are essential. It appears that PMO from most CAPD
patients, when tested in vitro in dialysate-free media, are able to
function as efficiently as normal PMN or monocytes [5, 11—13].
In the in vivo setting of peritoneal dialysis, however, every
dialysate exchange compromises peritoneal host defenses by
washing out and diluting cells and opsonins. In addition, with
every exchange a phagocytotoxic milieu is created by the high
osmolality and low pH of fresh glucose-based dialysis solutions
[14]. After instillation of dialysis fluid into the peritoneal cavity,
dialysate pH adjusts to levels which are noninhibitory for
peripheral blood leucocytes after 30 minutes; the changes in
osmolality, however, are less rapid and may remain at inhibi-
tory levels for fluids of high glucose concentrations [14]. Thus,
especially during the initial period of a dwell, the peritoneal
cells operate under extreme unphysiologic conditions. If this
causes impairment of essential cellular functions an at least
transitory increased risk of infection may result. Indeed, sev-
eral in vitro studies have demonstrated that exposure to fresh
peritoneal dialysis fluid (1.) reduces the viability of lymphocytes
[15], PMN [16] and PMO [171; (2.) inhibits the phagocytic and
bacterial killing capacity of PMN [14] and of PMO [16]; (3.)
impairs their respiratory and oxidative metabolism [18, 19]; (4.)
inhibits leucocytes to release inflammatory mediators in re-
sponse to adequate stimuli [20]. Peritoneal dialysis effluents
obtained after dwell times of 30 to 180 minutes have been shown
to suppress both PMO and PMN phagocytic capacity as well,
whereas effluents obtained after an overnight dwell did not
affect phagocytosis [16], suggesting phagocytic function to be
depressed for clinically relevant periods of the CAPD cycle. In
a previous study in CAPD patients [21], we demonstrated a
significant increase in the percentage of macrophages phagocy-
tizing opsonized sheep red blood cells and unopsonized latex
beads when dwell time increased from 1.5 to 15 hours. The
present study, using a bacterial challenge, reveals that the
impairment of peritoneal host defense mechanisms decreases
significantly later in the dwell time, once the dialysate has
reached physiologic pH and its osmolality has decreased.
The opsonic activity of effluents obtained after a dwell time of
15 hours was significantly higher than that of effluents obtained
after 4 hours, which can be ascribed to the rise in effluent IgG
and C3 levels with prolongation of dwell time. In addition, PMO
phagocytic capacity increased significantly with dwell time as
did PMO chemiluminescence response, the latter reflecting the
ability of PMO to mount a respiratory burst, that is, to produce
toxic oxygen radicals, which plays a key role in bacterial killing
[22].
The observed increase in PMO function with dwell time could
be due to the inflow of new cells into the peritoneal cavity; these
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newly arriving cells are exposed to a less detrimental milieu the
later in the dwell time period they appear. During CAPD it has
been estimated that 3 to 4 x l0 peritoneal macrophages are lost
each day in dialysate [51. The PMO turnover rate in humans
undergoing chronic peritoneal dialysis is, however, not known.
Recovery of resident macrophages from the detrimental
effects of fresh dialysis fluids during the intraperitoneal dwell of
such fluids may also contribute to the enhanced function of
PMO obtained after longer dwell times, which would suggest
that the impact of dialysis fluids on phagocyte functions is
reversible. The finding that PMO obtained from CAPD patients
incubated in tissue culture medium appear to express normal
phagocytic function [5, 13] is in favor of the latter hypothesis.
Anyway, longer dwell times that allow cells to recover and/or
repopulation of the peritoneal cavity, potentially improve the
host's resistance to peritonitis. The dialysis prescription inher-
ent to CAPD (three exchanges after 4 to 6 hr during the day, and
one exchange after 8 to 10 hr dwell overnight) differs from that
of CCPD (one long diurnal dwell time followed by 3 to 4
exchanges after 1.5 hr dwell time during the night). When
external occlusion is used in CCPD [23], open contact between
the peritoneal cavity and the environment is limited to only
once a day. This contamination-prone procedure is preceded by
a long diurnal dwell time, which we have shown to significantly
enhance the host defense status of the peritoneal cavity. CAPD
not only requires more frequent (dis)connection procedures,
but the connections are also preceded by shorter dwell times.
Thus, the dialysis regimen prescribed may have an impact on
peritonitis rates by its (dwell time related) effect on phagocytic
defense in instances where small numbers of bacteria contam-
inate the peritoneal cavity. In conclusion, no differences in
peritoneal host defense variables were found between chronic
CCPD and CAPD patients when dwell times were equal.
Prolonged dwell time enhanced effluent opsonic activity as well
as PMO functions, thereby providing a better local phagocytic
defense. As in CCPD with external occlusion the dwell time
period between contamination-prone procedures is much longer
(14 to 16 hr) than in CAPD, this might contribute to the lower
peritonitis incidence among CCPD-treated patients.
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